This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Extended-Spectrum Beta-Lactamases (ESBL)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • Extended-Spectrum Beta-Lactamases (ESBLs) are enzymes that can be produced by bacteria making them resistant to cephalosporins e.g. cefuroxime, cefotaxime and ceftazidime - which are the most widely used antibiotics in many hospitals
    • ESBLs were first described in the mid-1980s and during the 1990s were mostly found in Klebsiella species, mostly in hospitals and often in intensive care units treating the most vulnerable patients
    • a newer class of ESBL (called CTX-M enzymes) has emerged and these have been widely detected among Escherichia coli ( E. coli) bacteria
      • these ESBL-producing E. coli are able to resist penicillins and cephalosporins and are found most often in urinary tract infections - though not simple cystitis
      • have been found in the community as well as in hospitals, but patients with 'community acquired' infections may have had previous contact with hospitals

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.